Jakafi

Pharma

J&J, AbbVie's Imbruvica is first drug to treat kids with cGVHD

Johnson & Johnson and AbbVie’s Imbruvica has gained its first pediatric nod. This one is for chronic graft-versus-host disease.
Kevin Dunleavy Aug 25, 2022 9:37am

Incyte's Opzelura slapped with vitiligo decision delay

Mar 14, 2022 11:28am

Incyte's eczema cream Opzelura combats payer hurdles: exec

Nov 2, 2021 10:55am

Jakafi maker Incyte channels blood test anxiety in awareness ads

Oct 12, 2021 11:05am

Incyte snags 2nd JAK nod in 2 days—this time for Jakafi

Sep 23, 2021 10:20am

Incyte still counts on Jakafi, rux cream September PDUFAs

Aug 4, 2021 11:12am